Logo
IGF 1 LR3 1mg

IGF 1 LR3 1mg

IGF-1

Research Peptides & Biochemicals
  • Sold as a research Use Only (RUO) peptide and not authorised as a medicinal product by the UK MHRA, EMA, FDA or other major regulatory agencies.
  • Not a medical device and therefore not CE Marked or UKCA Marked for diagnostic or therapeutic use.
  • Use in laboratories is subject to general chemical safety, occupational health, and ethics regulations applicable in the jurisdiction of the end user.
  • Falls within classes of growth factors and related substances that are prohibited in competitive sport under anti Doping regulations, reinforcing that it must not be used for performance enhancement.
Insulin-like growth factor analog research peptide

Description

IGF-1 LR3 1mg is a research-grade peptide corresponding to a synthetic, modified analogue of human insulin-like growth factor-1 (IGF-1), known as long arginine 3 IGF-1. IGF-1 LR3 differs from native IGF-1 by the substitution of arginine for glutamic acid at position 3 and the addition of a 13-amino-acid N-terminal extension, giving a total of 83 amino acids instead of 70. These structural modifications markedly reduce its affinity for insulin-like growth factor binding proteins (IGFBPs) and increase its metabolic stability. As a result, IGF-1 LR3 retains IGF-1 receptor agonist activity while remaining bioactive far longer than native IGF-1, leading to much greater functional potency in experimental systems. Preclinical work uses IGF-1 LR3 to investigate cell proliferation, differentiation, protein synthesis, metabolism, and tissue repair pathways, including skeletal muscle hypertrophy, connective tissue remodelling and aspects of lactation biology. This product is supplied as 1mg lyophilised peptide intended strictly for laboratory research use and is not approved as a medicine, supplement, or cosmetic.

Bnefits

  • Synthetic long-acting analogue of IGF-1 that preserves agonist activity at the IGF-1 receptor while exhibiting reduced binding to IGF binding proteins, enhancing effective bioavailability in experimental models.
  • Modified structure (Arg substitution at position 3 plus a 13-amino-acid N-terminal extension) results in substantially prolonged half-life and activity compared with native IGF-1.
  • In vitro and animal studies show potent mitogenic and anabolic effects, promoting cell division, growth, and survival in a variety of cell types, including muscle, bone and cartilage.
  • Frequently used to study skeletal muscle hypertrophy, muscle repair and connective tissue remodelling, including pathways related to myostatin signalling and protein synthesis.
  • Experimental data suggest effects on metabolic processes such as lipid and glucose handling, enabling research into fat metabolism and energy balance.
  • Used in preclinical models exploring growth-factor signalling in lactation and maternal physiology, based on the broader role of IGF-1 in mammary gland development and milk production.
  • Provided as a defined 1mg lyophilised peptide, allowing precise preparation of stock solutions and controlled dosing in laboratory experiments.
  • Clearly labelled as research-use-only (RUO), helping maintain separation between scientific investigation and unregulated human administration.

Indications

  • For laboratory research use only in appropriately equipped facilities (e.g., in vitro cell culture, ex vivo tissue work, and ethically approved in vivo animal studies).
  • Mechanistic studies of insulin-like growth factor signalling, including IGF-1 receptor activation and downstream cascades such as PI3K/Akt/mTOR and MAPK.
  • Investigation of cell proliferation, survival, differentiation and apoptosis in muscle, cartilage, bone and other IGF-responsive tissues.
  • Preclinical research into skeletal muscle hypertrophy, regeneration, connective-tissue repair and recovery from injury.
  • Exploration of IGF-1–mediated effects on lipid and carbohydrate metabolism in metabolic and endocrine research models.
  • Experimental work on growth-factor roles in lactation, mammary gland development and maternal physiology, within approved research protocols.
  • Assay development, positive control reagent use, and validation of analytical platforms studying IGF-1 and related pathways.

Composition

  • Active component: IGF-1 LR3 (Long Arg3 insulin-like growth factor-1), a synthetic 83-amino-acid analogue of human IGF-1.
  • Structural modifications relative to native IGF-1: substitution of arginine for glutamic acid at amino acid position 3 and addition of a 13-amino-acid N-terminal extension.
  • Retains binding capability to IGF-1 and insulin receptors while exhibiting greatly reduced affinity for insulin-like growth factor binding proteins (IGFBPs).
  • Supplied as lyophilised peptide powder at a nominal content of 1mg per vial.
  • No specific excipients, preservatives or stabilisers are listed on the distributor website; preparation of working solutions is determined by the receiving laboratory.

Formulation

  • Presentation: lyophilised (freeze-dried) peptide in a sealed research vial.
  • Content: 1mg IGF-1 LR3 peptide per vial (nominal).
  • Intended reconstitution by the end user using suitable sterile solvents or buffers under laboratory conditions to obtain desired experimental concentrations.
  • Not formulated with carriers, vehicles or excipients for human administration and not provided with clinical dosing instructions.
  • Marketed as a research-use-only peptide reagent rather than as a medicinal product, dietary supplement or cosmetic.

Packaging

  • Primary packaging: sealed vial containing 1mg lyophilised IGF-1 LR3 peptide.
  • Vial typically constructed from glass with an appropriate closure (rubber stopper and cap or screw-top), consistent with standard research peptide presentation.
  • Secondary protective packaging (e.g., foam inserts, cartons or padded mailers) used for shipping to limit mechanical damage and temperature excursions.
  • Outer shipping carton labelled according to courier and supplier requirements as containing research chemicals, not for human consumption.
  • No patient-facing packaging, leaflet or regulatory approval markings, in line with research-use-only status.

Usage

  • Use only in accredited research laboratories by trained personnel familiar with handling biologically active peptides and research chemicals.
  • Before opening, allow the vial to reach appropriate handling temperature to minimise condensation; open in a clean environment and avoid creating dust or aerosols.
  • Reconstitute the lyophilised peptide with sterile, suitable solvent or buffer according to internal laboratory protocols, recording final concentration and batch details.
  • If required, prepare aliquots to avoid repeated freeze–thaw cycles and store according to institutional guidelines for peptide stability.
  • Handle all solutions with appropriate personal protective equipment (PPE), including lab coat, gloves and eye protection.
  • Do not ingest, inject or apply the peptide to humans or animals outside ethically approved experimental protocols; this compound is not approved for therapeutic use.
  • Dispose of unused peptide, vials and contaminated consumables as laboratory chemical/biological waste in accordance with local regulations and institutional policies.
  • Follow all applicable biosafety, chemical safety and occupational health regulations governing research peptide use.

Contraindications

  • Contraindicated for any form of human or non-research animal administration; it is not an approved drug, supplement or cosmetic ingredient.
  • Should not be used outside properly equipped research and development facilities or by individuals lacking appropriate training in laboratory safety.
  • Do not use in experiments lacking required ethical approval (e.g., institutional animal care and use or equivalent oversight) where such approval is mandated.
  • Avoid use where appropriate engineering controls, PPE and waste-disposal systems are not in place to manage potential exposure.
  • Personnel with known hypersensitivity to laboratory peptides, or with occupational restrictions regarding exposure to growth factors, should follow relevant occupational health guidance and may need to avoid direct handling.

Adverse Effects

  • No formal safety profile in humans is established; potential adverse effects of any unsanctioned human exposure are unknown and could be serious, including effects on metabolism, growth regulation and tumour biology.
  • As with other biologically active peptides, accidental exposure of laboratory personnel (e.g., via skin contact, sharps injury or inhalation of aerosols) may pose theoretical health risks and should be managed according to institutional incident protocols.
  • Preclinical research on IGF-1 analogues indicates potent anabolic and mitogenic activity, which is one reason these substances are tightly controlled and prohibited in competitive sport; such properties underscore the importance of limiting use to controlled research contexts.
  • Unregulated self-experimentation or performance-enhancement use is strongly discouraged due to possible risks such as hypoglycaemia, soft-tissue overgrowth, joint pain and potential long-term impacts on cancer risk suggested for dysregulated IGF-1 signalling.

Storage Conditions

  • Store lyophilised vials in a freezer at temperatures typically at or below -20°C, protected from light and moisture, in line with general guidance for peptide stability and any specific manufacturer recommendations if supplied.
  • Keep vials tightly sealed until reconstitution to minimise exposure to ambient humidity and degradation.
  • After reconstitution, store peptide solutions at temperatures and for durations supported by internal stability data (e.g., short-term at 2–8°C, longer-term in aliquots frozen to avoid repeated freeze–thaw cycles).
  • Ensure storage areas are access-controlled so that only authorised laboratory personnel can handle the product.
  • During shipment, use appropriate insulated packaging and cold-chain measures if required to limit temperature excursions and maintain peptide integrity.

Duration

Not applicable; IGF-1 LR3 1mg is a research-use-only peptide with no authorised therapeutic regimen or approved treatment duration in humans or clinical veterinary practice.

Onset

Not defined for clinical use; in experimental systems, the time course of action depends on model design, exposure conditions and analytical endpoints rather than any approved therapeutic indication.

Browse more Research Peptides & Biochemicals

Top Treatments

Top Cities in the UK